Pharma Jonpi . / 1.1 / .
12 febrero 2019
Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma .
‹
›
Inicio
Ver versión web